SCLC, researchers aimed to determine the consistency of benefit of adding PD-1/PD-L1 inhibitors to platinum-etoposide.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab), in ...
Frontline gastric/GE junction cancer care now pairs chemo with checkpoint inhibitors for PD-L1 CPS≥1, improving survival and ...
The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or ...
Efficacy and safety analysis on the combination of camrelizumab with nab-paclitaxel and cisplatin-based chemotherapy in first-line treatment of advanced or metastatic esophageal squamous cell ...
(A) PDL1Nb, CTLA-4, Luc pDNA construction. (B) IB analysis shows the levels of PDL1Nb or CTLA-4Nb in the SFM of HEK293 cells transfected with PDL1Nb, CTLA-4Nb or Luc expression vectors. Mock: SFM.
Combining PD-L1 blockade with pharmacological HPK1 inhibition overcomes tumors with low antigenicity
An article by Daiichi Sankyo Co. Ltd. scientists reports data from a study designed to assess the potential of combining pharmacological inhibition of hematopoietic progenitor kinase 1 (HPK1) with ...
The Food and Drug Administration (FDA) has approved Tecentriq Hybreza ™ (atezolizumab and hyaluronidase-tqjs) for subcutaneous (SC) injection, for all the approved adult indications of intravenous ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results